A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-55143-0
Abstract: G-protein-coupled receptor class 5 member D (GPRC5D) is detected in malignant plasma cells in approximately 90% of patients diagnosed with multiple myeloma (MM). Here, we constructed BsAb5003, a novel humanized bispecific monoclonal antibody targeting CD3… read more here.
Keywords: multiple myeloma; bsab5003; cell redirecting; antibody ... See more keywords
Abstract 1883: A novel T cell engager targeting BCMA and GPRC5D showed promising preclinical activity with low toxic risk for multiple myeloma treatment
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1883
Abstract: Background: Multiple myeloma (MM) has become the second most hematological malignance. The patients are rarely cured and experience the recurrence or resistance. There is still an urgent need to develop potential therapeutic agents with better… read more here.
Keywords: cell; gprc5d; bcma; scr 8572 ... See more keywords
Abstract 5206: A novel mouse model for preclinical efficacy evaluation of anti-CD3/GPRC5D bispecific antibodies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5206
Abstract: The FDA has granted Breakthrough Therapy Designation (BTD) for talquetamab, which targets both GPRC5D on multiple myeloma cells and CD3 on T-cells, for treating adult patients with relapsed or refractory multiple myeloma. Results showed that… read more here.
Keywords: anti cd3; gprc5d bispecific; gprc5d; cd3 gprc5d ... See more keywords
Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200593
Abstract: Background: G protein-coupled receptor class C group 5 member D (GPRC5D) has recently emerged as a promising immunotherapy target in Multiple Myeloma (MM) although its function remains unknown. Mono-allelic GPRC5D alterations are found in 15%… read more here.
Keywords: del; talquetamab; gprc5d; cell ... See more keywords
Discovery of JNJ-87562761, a novel anti-GPRC5D enhanced effector function (eEF) antibody with multiple mechanisms of action for the treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3934
Abstract: Antibody and cellular therapies have reshaped the multiple myeloma (MM) therapeutic landscape in recent years resulting in significantly improved clinical outcomes. These therapies target plasma cell antigens such as CD38, B cell maturation antigen (BCMA)… read more here.
Keywords: antibody; anti; jnj 87562761; cell ... See more keywords
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5785
Abstract: Introduction: No other hematologic malignancy has seen more drug approvals than multiple myeloma (MM). Yet, MM remains largely incurable, even in the era of T-cell engaging therapies. Patients who have exhausted all treatment options can… read more here.
Keywords: evolution; bcma; loss; gprc5d ... See more keywords
QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase Ⅰa study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5831
Abstract: Background: Bispecific antibodies targeting B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D) are revolutionizing the treatment landscape of multiple myeloma. Trispecific antibody (TsAb) simultaneously targeting BCMA and GPRC5D… read more here.
Keywords: bcma; treatment; response; cell ... See more keywords
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood.2024026622
Abstract: G protein-coupled receptor, class C, group 5, member D (GPRC5D) has emerged as a novel target for chimeric antigen receptor (CAR) T-cell therapy, demonstrating promising efficacy in multiple myeloma (MM). However, disease relapse is still… read more here.
Keywords: cell therapy; loss; car cell; cell ... See more keywords
Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2025.1607778
Abstract: Chimeric antigen receptor (CAR) -T cell therapy targeting B-cell maturation antigen (BCMA) has demonstrated significant efficacy and is considered an ideal target for the treatment of relapsed or refractory multiple myeloma (R/R MM). However, due… read more here.
Keywords: cell therapy; car cell; gprc5d; car ... See more keywords